4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

4 - PLIANT THERAPEUTICS, INC. (0001746473) (Issuer)

Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported first quarter 2025 financial results. "During the first quarter and over recent weeks, our teams have been working diligently to close out the g

-  Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials -  Pliant will reduce its current workforce by approximately 45% -  Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support execution of late-stage clinical trials. The restructuring aims to minimize costs and preserve cash reserves as the Company awaits topline data from the BEACON-IPF Phase 2b/3 trial of be

SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025. The following abstracts are posted on ATS 2025's online itinerary planner for registered users. Pliant was selected for a featured oral presentation as part of the ATS 2025 Mini Symposiums program. Title: Characterizing the Antifibrotic Activity of Bexotegrast on Distinct Fibroblast Populations in PCLS From Multiple ILD SubtypesPresenter: Johanna Schaub, Ph.D., Director of T

Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an integrin αvβ8 and αvβ1 inhibitor, in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI) -refractory advanced or metastatic solid tumors. Interim results demonstrated PLN-101095 anti-tumor activity in combination with

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that following a prespecified data review and recommendation by the trial's independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in unadjudicated IPF-related adverse events between the treatment and placebo groups led to the discontinuation of the trial, early evidence of efficacy on the forced vital capacity (FVC) endpoint was also observed. BEACON-IP

SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that, per the charter of the trial's independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). The panel, consisting of world-renowned experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the BEACON-IPF trial. Subsequently, the panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation reg

Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). Patients currently enrolled in BEACON-IPF will remain in the trial. Enrollment and dosing have been paused

SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced that on January 21, 2025, it granted stock options to purchase an aggregate of 275,000 shares of common stock upon vesting to Delphine Imbert, Ph.D., the Company's newly appointed Chief Technical Officer, as a material inducement to her employment. The stock options that were granted are subject to an exercise price of $11.07 per share, which is equal to the closing price of the Company's common stock on January 21, 2025, and will vest over 4 years, with 25% of the shares underlying the employee's option vesting on the one-year anniversary of the grant date and the remai

10-Q - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

DEFA14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

DEF 14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

PRE 14A - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

8-K - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

8-A12B - PLIANT THERAPEUTICS, INC. (0001746473) (Filer)

SCHEDULE 13D - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SCHEDULE 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

Needham downgraded Pliant Therapeutics from Buy to Hold

Cantor Fitzgerald resumed coverage of Pliant Therapeutics with a rating of Neutral

Stifel downgraded Pliant Therapeutics from Buy to Hold

Leerink Partners downgraded Pliant Therapeutics from Outperform to Market Perform

Analyst downgraded Pliant Therapeutics from Overweight to Neutral

Canaccord Genuity downgraded Pliant Therapeutics from Buy to Hold and set a new price target of $4.00 from $43.00 previously

Oppenheimer downgraded Pliant Therapeutics from Outperform to Perform

Citigroup downgraded Pliant Therapeutics from Buy to Neutral and set a new price target of $4.00 from $40.00 previously

Wells Fargo downgraded Pliant Therapeutics from Overweight to Equal Weight and set a new price target of $4.00 from $41.00 previously

RBC Capital Mkts downgraded Pliant Therapeutics from Outperform to Sector Perform and set a new price target of $4.00 from $5.00 previously

SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

SC 13G/A - PLIANT THERAPEUTICS, INC. (0001746473) (Subject)

Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF discontinued following recommendation from expanded data safety monitoring board (DSMB). Following a prespecified data review and recommendation by the trial's independent DSMB, as well as a secondary r

Dr. Imbert brings 25 years of strategic clinical to commercial-stage manufacturing and drug development experience SOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Delphine Imbert, Ph.D. as Chief Technical Officer. Dr. Imbert brings 25 years of product development, process optimization and manufacturing experience across multiple drug modalities, including small molecules. In this role, Dr. Imbert will lead chemistry, manufacturing and control (CMC)-related acti

BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2024 financial results. "A highlight to this quarter's progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is enrolling well and on track to complete enrollment in the first quarter of 2025," said Bernard Coulie, M.D., Ph.D.

Former Bristol Myers Squibb Global Medical Affairs Lead brings over 25 years of experience to Pliant SOUTH SAN FRANCISCO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Gary Palmer, M.D., MBA as Senior Vice President of Medical Affairs. Dr. Palmer will lead the Company's global medical affairs activities including scientific communications and patient advocacy. "Gary brings deep global medical affairs leadership and strategic expertise in supporting successful and orphan disease

SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced the appointment of Dr. Hardean Achneck as Chief Medical Officer, effective immediately. Dr. Achneck will lead the Company's global clinical development efforts and serve as a member of Aligos' Senior Leadership Team. Dr. Hardean Achneck is a seasoned clinical development executive with extensive experience across multiple therapeutic areas, including hepatology and infectious diseases. "I am excited to welcome Hardean to Aligos a

CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (NASDAQ:KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, today announced that the Board of Directors has appointed Katharine Knobil, M.D. as an Independent Director, effective immediately. Korro also announced that David Lucchino has stepped down from the Board. Dr. Knobil brings a wealth of experience in clinical development and regulatory affairs to Korro. With over 25 years in the pharmaceutical and biotech industries, she has played a pivotal role in advancing numerous therapeutics from early-stage develo

Positive data from a 12-week Phase 2a PET imaging trial demonstrated reduced total lung collagen, improved FVC and reduced cough severity in IPF patients treated with bexotegrast Positive long-term data from INTEGRIS-PSC 320 mg dose group demonstrated bexotegrast was well tolerated with continued antifibrotic and anti-cholestatic activity observed at 24 weeks across multiple measures BEACON-IPF Phase 2b trial on track for full enrollment in the first quarter of 2025 with data anticipated in mid-2026 SOUTH SAN FRANCISCO, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage clinical biotechnology company and leader in the discovery and

SOUTH SAN FRANCISCO, June 13, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a late-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today announced the appointment of Steve Krognes to its Board of Directors. "Steve is a tremendous addition to our board, bringing extensive strategic leadership experience and a depth of financial expertise that will benefit Pliant's continued evolution as a late-stage clinical company," said Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant. "Steve's broad financial experience will be highly complimentary to the strong science

Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a biotechnology company that designs and develops breakthrough medicines for patients through its powerful computational drug discovery engine, today announced that Katharine Knobil, M.D., has been appointed to the Company's Board of Directors. Dr. Knobil is a seasoned executive with more than 20 years of experience in pharmaceutical research and product development including global clinical research, medical affairs, and patient safety. "We are honored to welcome Dr. Knobil to our Board of Directors as we embark on the next exciting chapter at Nimbus with plans to accelerate and expand our development programs in multiple ther

Positive interim 12-week safety and efficacy data reported from Phase 2a INTEGRIS-PSC trial in patients with PSC Positive DSMB safety review recommends INTEGRIS-PSC trial continue without modification Key Clinical Development and Regulatory appointments expand leadership team SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported third quarter 2023 financial results. "The third quarter was highlighted by positive interim data from th

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company's common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take

Bexotegrast (PLN-74809) at 320 mg was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events; No safety concerns identified across all dose cohorts Bexotegrast at 320 mg reduced liver fibrosis markers ELF and PRO-C3 and showed improvements in hepatocyte function and bile flow by contrast MRI imaging relative to placebo at Week 12 The 320 mg data continue to demonstrate antifibrotic effects of bexotegrast, consistent with previous findings Company to host webcast and conference call tomorrow, Monday, February 5 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Feb. 04, 2024 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced

Bexotegrast (PLN-74809) was well tolerated over 12 weeks of treatment with few discontinuations and no drug-related severe or serious adverse events Bexotegrast reduced both the Enhanced Liver Fibrosis (ELF) score and collagen synthesis biomarker PRO-C3 levels relative to placebo at all doses with statistical significance at the 160 mg dose Bexotegrast-treated patients showed improved liver biochemistry and imaging parameters relative to placebo at Week 12 Company to host webcast and conference call today, Tuesday, September 26 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data f

SOUTH SAN FRANCISCO, Calif., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced it will host a conference call and webcast on Tuesday, September 26, 2023 at 8:00 a.m. ET | 5:00 a.m. PT to discuss the interim results from the INTEGRIS-PSC Phase 2a trial. Members of Pliant's management will be joined by Gideon Hirschfield, FRCP, Ph.D., Lily and Terry Horner Chair in Autoimmune Liver Disease at the University of Toronto and a principal investigator in the INTEGRIS-PSC trial. The conference call will be simultaneously webcast online and will be accessible from the Events & Presentation section of Pliant's website. The live audio of the conference call c

Bexotegrast was well tolerated up to 40 weeks of treatment with no drug-related serious adverse events Combination of bexotegrast with standard of care reduced FVC decline by 80% relative to standard of care alone at Week 24 89% of bexotegrast-treated patients with an increase in FVC from baseline at Week 12 maintained an increase at Week 24 Stabilization of fibrosis as measured by QLF imaging was observed in the bexotegrast group while the placebo group showed progression of fibrosis at Weeks 12 and 24 A reduction in patient-reported cough severity was reported in the bexotegrast group in contrast to worsening in the placebo group BEACON-IPF Phase 2b trial to be initiated in mid-2023

Bexotegrast demonstrated statistically significant increase in FVC at 4, 8 and 12 weeks of treatment, outperforming lower dose groups No bexotegrast-treated patients experienced disease progression as defined by FVCpp decline of greater than or equal to 10% Bexotegrast was well tolerated over 12 weeks of treatment with no drug-related severe or serious adverse events Company to host webcast and conference call tomorrow, Monday, January 23rd at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Jan. 22, 2023 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX) today announced 12-week interim data from the 320 mg dose group of INTEGRIS-IPF, a multinational, randomized, double-blind, pla

PLN-74809 demonstrated a dose-dependent treatment effect on FVC and QLF versus placebo over 12 weeks of treatment PLN-74809 treatment effect was observed on top of standard of care therapy and as monotherapy PLN-74809 was well tolerated over 12 weeks of treatment with no drug related SAEs and no treatment discontinuations due to adverse events Company to host webcast and conference call tomorrow, Monday July 11 at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., July 10, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), today announced positive data from INTEGRIS-IPF, a multinational, randomized, double-blind, placebo-controlled Phase 2a clinical trial of PLN-74809 in patient

- Single dose administration of PLN-74809 achieved αvβ6 target engagement up to 98% in the lungs of IPF patients - All doses achieved target engagement above the threshold for predicted anti-fibrotic activity, with an observed dose-response relationship- PLN-74809 reached highly fibrotic regions of the lung and was bound to αvβ6 in IPF patients - Data provide insight into potential anti-fibrotic activity of PLN-74809 at the doses being evaluated in the ongoing Phase 2a INTEGRIS-IPF trial - Company to host conference call and webcast today at 8:00 a.m. ET SOUTH SAN FRANCISCO, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnolog

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (NASDAQ:PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that the Company plans to issue a pre-market press release and conduct a conference call and webcast on Tuesday, September 7, 2021, to discuss interim clinical data from an ongoing Phase 2a positron emission tomography (PET) imaging trial of PLN-74809 in patients with idiopathic pulmonary fibrosis (IPF). The Company will host a conference call and webcast at 8:00 a.m. ET on Tuesday, September 7th to discuss this update. The link to the webcast o

- PLN-74809 Phase 2a PET Imaging Trial Resumed, with Preliminary Data Expected First Half of 2021 - PLN-74809 Phase 2a 12-week trials in IPF and PSC Gained Momentum in the Fourth Quarter, Currently on Track to Complete Enrollment by the End of 2021 and First Half of 2022, Respectively SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) (the Company), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today provided a corporate update and reported fourth quarter and full year 2020 financial results. “We entered 2021 in a strong position resulting from our team’